ARTICLE | Finance

Enriched by Enobia

Alexion-Enobia could be biggest takeout deal for private clinical stage biotech

January 2, 2012 8:00 AM UTC

OrbiMed Advisors could make more money from Alexion Pharmaceuticals Inc.'s acquisition of Enobia Pharma Inc. than is in the entire fund that contains the investment.

Last week, Alexion (NASDAQ:ALXN) said it would buy the metabolic company for $610 million up front and up to $470 million in milestones (see "Ultra-rarified Heir," A20)...